AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06215950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
Study NCT05396248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Retraining Exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
Study NCT05396248 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Memory Exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
Study NCT05468112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKY Meditation and Mindfulness
Description: The intervention is a 3-day in-person meditation and mindfulness workshop using the SKY meditation approach. It utilizes a unique set of standardized breathing techniques to rapidly reduce neuro-endocrine stress responses and the autonomic imbalance due to sympathetic overdrive, thus restoring autonomic homeostasis. These are interwoven with coping and stressor appraisal strategies, and simple stretching exercises. Classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions with an additional 7 consecutive days of online sessions immediately thereafter. In addition, participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. They will complete a follow-up session once per week in the subsequent 8 weeks.
Study NCT04989959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PT2385
Description: \[18F\]PT2385 infusion
Study NCT04989959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan after \[18F\]PT2385 infusion
Study NCT04989959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: CT-guided tumor biopsy
Study NCT06015867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention with Wholemeal Bread with Yeast
Description: Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).
Study NCT06015867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention with Wholemeal Sourdough Bread
Description: Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
Study NCT05108792 — intervention group
Intervention type: OTHER
Intervention: NO INTERVENTION
Description: observational study, no intervention performed
Study NCT06359665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 500 mg capsule twice daily
Study NCT06359665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule twice daily
Study NCT06117280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraxanthine 200 mg
Description: For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.
Study NCT06117280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraxanthine 300 mg
Description: For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.
Study NCT06117280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.
Study NCT04931420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care Chemotherapy
Description: * If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~* If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~* If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered.
Study NCT04931420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracic Surgery (VATS)
Description: If you have lung cancer, you may receive video-assisted thoracic surgery (VATS): a type of minimally invasive thoracic surgery of the chest, performed with a thoracoscope (small videoscope) using small incisions and special instruments to minimize trauma.
Study NCT04931420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy
Description: If you have lung cancer, you may receive a lobectomy:~A major/invasive surgical procedure where an entire lobe of your lung is removed.
Study NCT04931420 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidative Radiation
Description: A type of radiation treatment used to kill any cancer cells that may be left in the body. It may also include a stem cell transplant or treatment with drugs that kill cancer cells.
Study NCT04931420 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ablation Treatment
Description: Depending on the location of you cancer and the state of your cancer after chemotherapy, you may receive on the the following ablation treatments:~-Microwave or Radiofrequency Ablation: Radiofrequency ablation (RFA) and microwave ablation (MWA) are treatments that remove liver tumors by placing a needle through the skin into the tumor. In RFA, high-frequency electrical currents are passed through an electrode in the needle, creating a small region of heat. In MWA, microwaves are created from the needle to create a small region of heat. The heat destroys the liver cancer cells.~-General Tumor Ablation Treatment: a minimally invasive surgical method to treat solid cancers. Special probes are used to burn or freeze cancers without the usual surgery. Doctors use images of your tumor to guide where they place the needle. This requires only a tiny hole, usually less than 3 mm via which the probe is introduced.
Study NCT04931420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection or Excision
Description: Depending on the type of GI cancer you have and the state of your cancer after chemotherapy, you may receive a resection or excision: a surgical procedure that focuses on removing all or part of a tumor/organ/body using a sharp knife (scalpel) or other cutting instrument.
Study NCT04931420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritonectomy
Description: Peritonectomy is a surgery used to remove peritoneal tumors (tumors in the lining of the abdomen/stomach) from a patient. Following surgery, a heated chemotherapy bath (HIPEC) is commonly administered.
Study NCT04931420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transarterial Radioembolization
Description: If you have cancer in your biliary tract (gallbladder, pancreas or liver), you may receive transarterial radioembolization known as TARE.~TARE allows doctors to deliver radiation treatment directly to the liver using a minimally invasive technique that is designed to cause few side effects. TARE allows doctors to thread a catheter through a small incision in the participant's upper thigh through the artery that goes directly to the liver.
Study NCT05974748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite 5.25%
Description: The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
Study NCT05974748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis 20%
Description: In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
Study NCT05708612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical Device (SimplyFI)
Description: Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
Study NCT05945875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given by IV
Study NCT05945875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indium In 111 Panitumumab
Description: Given by IV
Study NCT05945875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo Single Photon Emission Computed Tomography
Study NCT05945875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Computed Tomography
Study NCT05945875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo standard of care surgical resection
Study NCT05945875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo standard of care fluorescence imaging
Study NCT04808401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
Study NCT04728347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021
Description: ARCT-021 single dose
Study NCT05337306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GogyUp Reader
Description: Participants will have unlimited access to the assistive-reading technologies available in the GogyUp Reader app for help understanding post-visit educational documents on type 2 diabetes mellitus disease management.
Study NCT06083207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3003
Description: Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
Study NCT06449638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT06449638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revita
Description: Participants will receive weekly applications of Revita and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT06449638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relese
Description: Participants will receive weekly applications of Relese and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT06449638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cogenex
Description: Participants will receive weekly applications of Cogenex and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT06449638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enverse
Description: Participants will receive weekly applications of Enverse and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT05584410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient information
Description: Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
Study NCT05584410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient information
Description: Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
Study NCT05584410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone application based exercises
Description: Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
Study NCT05584410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web based exercises
Description: Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description
Study NCT05584410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group based information
Description: Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
Study NCT05584410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised rehabilitation
Description: The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
Study NCT05584410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
Study NCT05584410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational notifications
Description: Automatic and daily reminders and / or motivational notifications
Study NCT05584410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based rehabilitation
Description: Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
Study NCT06648772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream 0.3%
Description: Roflumilast Cream 0.3%
Study NCT06648772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream
Study NCT05978921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength physical exercise programme
Description: 12 multi-joint strength exercises will be developed. Participants will be taught the rating scale of perceived exertion (RPE) based on the number of repetitions in reserve (RIR). Participants will be asked that during the performance of each of the exercises they must perceive an effort between 7-8 within the overall score of the scale (0-10; 0 = no effort at all and 10 = cannot perform one more repetition, i.e. maximal effort). When subjects perform the 12 repetitions with lower perceived exertion than the set effort in two consecutive sessions with full range of motion the training load will be increased by about 2-10% following the American College of Sports Medicine guidelines and reassessed using the RIR-based RPE. Patients in the usual treatment group will continue to participate in their existing rehabilitation programmes, but will not be included in the strength training programme.
Study NCT05978921 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal life
Description: Normal life and carry out all the activities they have been doing previously.
Study NCT05920629 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alcohol consumption
Description: After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (\<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 12 months. We will perform a first echocardiography at randomization and a second at 12 months' follow-up.
Study NCT04732455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine in Saline
Description: Lidocaine IV infusion (2 mg/kg) in 200 ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle.
Study NCT04732455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: Oral Duloxetine tablet 30 mg once per day starting from the night pre chemotherapy during the whole period of chemotherapy cycle which expected to be three month
Study NCT04732455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
Study NCT05289362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basket group
Description: Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.
Study NCT05289362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon group
Description: Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
Study NCT04321538 — intervention group
Intervention type: DEVICE
Intervention: Gocheck Kids
Description: GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.
Study NCT04321538 — intervention group
Intervention type: DEVICE
Intervention: Welch Allyn Spot Vision Screener
Description: The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.
Study NCT04321538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physical Exam
Description: Retinoscopy and an oculomotor testing will constitute the physical examination.
Study NCT05712590 — intervention group
Intervention type: OTHER
Intervention: dietary habit
Description: As it is observational study, women that follow three different dietary patterns will be inlcuded .
Study NCT06135337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thioderm Elate
Description: Test Device
Study NCT06135337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Ultra 3
Description: Active Comparator Device
Study NCT06307587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: The vastus intermedius will be approached with DN from the lateral aspect and the pincer approach will be followed. The Hong fast-in and fast out technique with multiple rapid needle insertions will be performed following previous recommendations (Chou, et al., 2014). The control group will receive the rehabilitation program alone. A headless 0.25 × 25-mm needle (Stainless steel, Agupunt A1038P, 158 Caspe, Barcelona, Spain) will be used. The penetration depth will be varied according to the patient. Hemostasis will be performed for 1 minutes. DN will be performed medial to the sartorius muscle limit to avoid saphenous nerve adverse effects during DN (Henry et al., 2016).
Study NCT05708872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autohypnosis
Description: Patients in the study group will receive a voice recording with hypnotic instructions with a suggestion to improve the psychophysical state.
Study NCT06230289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal plane block
Description: Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (by using envelope selection method) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group B will receive a four-point TAP block, while no interventional procedures will be performed on patients in Group C.
Study NCT06475612 — intervention group
Intervention type: OTHER
Intervention: Death
Description: Mortality group.
Study NCT06475612 — intervention group
Intervention type: OTHER
Intervention: Survival
Description: Survival group.
Study NCT06164717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory feedback perturbation during speech
Description: The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
Study NCT06164717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual feedback perturbation during reaching
Description: The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.